Лефлуномид в лечении псориатического артрита

Мусина Флариса Сабирьяновна, П. Д. Болотов, Zarema Rimovna Khismatullina et al. · Медицинский вестник Башкортостана · 2011

The article presents the results of the evaluation of the effectiveness and portability of Leflunomide, which is appointed for the patients with psoriatic arthritis (PA) in dose 100 mg for a day in 3 days and 20 mg for a day in 6 months. 24 patients in the age from 32 till 60 years (middle age 46,5±5,6 year) with prescription of disease from 6 months till 10 years was surveyed. Leflunomide was appointed on 100 mg for a day in the first 3 days, and then 20 mg for a day during 6 months. The dynamics of number of the painful and inflamed joints, expressivenesses of a pain and activity of disease was estimated on a visually-analog scale and Likert scale as in opinion of the doctor, and the patient. During the treatment by leflunomide the authentic reduction of number of painful and the inflamed joints was observed, high efficiency of leflunomide by criteria PsARC (Psoriatic Arthritis Response Criteria) and ACR 50 (American College of Rheumatology) was noted, which allows to recommend it to the patients with the articulate form of disease. The evaluation of leflunomide is estimated as satisfactory. High efficiency of leflunomide at patients with PA was shown.

Cited by 0 works.

Authors